Determination of ilaprazole in beagle plasma and its pharmacokinetics by high performance liquid chromatography-mass spectrometry

被引:2
|
作者
Zhou Lijun [1 ,2 ]
Li Jinglai [2 ]
Wang Xiaoying [2 ]
Qiao Jianzhong [2 ]
Zhang Zhenqing [2 ]
机构
[1] Chinese Peoples Liberat Army, Gen Hosp, Beijing 100853, Peoples R China
[2] Beijing Inst Pharmacol & Toxicol, Beijing 100850, Peoples R China
关键词
high performance liquid chromatography-electrospray ionization mass spectrometry (HPLC-ESI-MS); ilaprazole; beagle plasma; pharmacokinetics;
D O I
10.3724/SP.J.1123.2011.12081
中图分类号
O65 [分析化学];
学科分类号
070302 ; 081704 ;
摘要
A sensitive, simple and specific high performance liquid chromatography-electro spray ionization mass spectrometry method was developed for the determination of ilaprazole in the plasma of beagles administered via i.v. bolus doses of ilaprazole. The procedure employed buspirone as the internal standard and a simple protein precipitation step. The separation was achieved using a C18 column (100 mm x 2.1 mm, 5 mu m) with a mobile phase consisting of water-methanol-acetonitrile (69:8:23, v/v/v) containing 0.1% (v/v) formic acid at a flow rate of 0.2 mL/min. The detection was accomplished by a mass spectrometer using selected ion monitoring (SIM) in positive mode. The linearity was from 5 mu g/L to 10,000 mu g/L with a sensitivity of 5 mu g/L as the lower limit of quantification. The inter- and intra- day precisions were within 9.00%. The mean recoveries at three spiked levels were about 106% and the matrix effects were less than 142.0%. The method described above was successfully applied to analyze the beagle plasma samples of ilaprazole in a pharmacokinetic study. The area under the plasma concentration-time curve (AUC((0-infinity))) of ilaprazole after i.v. doses of 0.2, 0.8 and 3.2 mg/kg were (2.4 x 10(4) +/- 3 x 10(3)), (8.8 x 10(4) +/- 1.6 x 10(4)) and (5.4 x 10(5) +/- 8 x 10(4)) mu g/L x min, respectively. On the basis of AUC, the pharmacokinetic property of ilaprazole was proposed to be linear dynamics.
引用
收藏
页码:452 / 456
页数:5
相关论文
共 14 条
  • [1] Cho H, J CLIN PHARMACOL, DOI [10.1177/00091270011408611, DOI 10.1177/00091270011408611]
  • [2] Acid inhibition effect of ilaprazole on Helicobacter pylori-negative healthy volunteers: An open randomized cross-over study
    Du, Yi Qi
    Guo, Wen Yuan
    Zou, Duo Wu
    Zhan, Xian Bao
    Li, Zhen
    Hu, Jin Hong
    Gong, Yan Fang
    He, Jia
    Lu, Jian Ping
    Li, Zhao Shen
    [J]. JOURNAL OF DIGESTIVE DISEASES, 2012, 13 (02) : 113 - 119
  • [3] Randomized, parallel, double-blind comparison of the ulcer-healing effects of ilaprazole and omeprazole in the treatment of gastric and duodenal ulcers
    Ho, Khek Yu
    Kuan, Arlene
    Zano, Felix
    Goh, Khean Lee
    Mahachai, Varocha
    Kim, Dong Yeon
    Yoon, Hwan Min
    [J]. JOURNAL OF GASTROENTEROLOGY, 2009, 44 (07) : 697 - 707
  • [4] Kim EJ, 2001, ARZNEIMITTEL-FORSCH, V51, P51
  • [5] Kwon D, 2001, ARZNEIMITTEL-FORSCH, V51, P204
  • [6] Pharmacokinetics of the new proton pump inhibitor ilaprazole in Chinese healthy subjects in relation to CYP3A5 and CYP2C19 genotypes
    Li, Yalin
    Zhang, Wei
    Guo, Dong
    Zhou, Gan
    Zhou, Honghao
    Xiao, Zhousheng
    [J]. CLINICA CHIMICA ACTA, 2008, 391 (1-2) : 60 - 67
  • [7] Identification of IY81149 and its metabolites in the rat plasma using the on-line HPLC/ESI mass spectrometry
    Myung, SW
    Min, HK
    Jin, C
    Kim, M
    Lee, SM
    Chung, GJ
    Park, SJ
    Kim, DY
    Cho, HW
    [J]. ARCHIVES OF PHARMACAL RESEARCH, 1999, 22 (02) : 189 - 193
  • [8] Sachs G, 1997, PHARMACOTHERAPY, V17, P22
  • [9] Ilaprazole, a new proton pump inhibitor, is primarily metabolized to ilaprazole sulfone by CYP3A4 and 3A5
    Seo, Kyung-Ah
    Lee, So-Jeong
    Kim, Kwon-Bok
    Bae, Soo Kyung
    Liu, Kwang-Hyeon
    Kim, Dong-Hyun
    Shin, Jae-Gook
    [J]. XENOBIOTICA, 2012, 42 (03) : 278 - 284
  • [10] Sun, 2002, CHIN J CLIN PHARM TH, V7, P562